The fall in Erasca after its disclosure boosted fortunes of its rival RevMed, which surged 10%. The stock is up nearly 60% in the last one month after posting results of a late-stage trial earlier this month.
The fall in Erasca after its disclosure boosted fortunes of its rival RevMed, which surged 10%. The stock is up nearly 60% in the last one month after posting results of a late-stage trial earlier this month.